Pancreatic adenocarcinoma is an aggressive cancer with an overall 5-year survival of 5% or less. In patients who have resectable tumors, resection can lead to an improvement in overall survival, but local and distant recurrence rates remain high. Adjuvant therapy has demonstrated mixed results in clinical trials; thus the optimal adjuvant treatment of resected pancreatic cancer remains unclear. The purpose of this article is to review and assess the pertinent literature and try to determine an acceptable and uniform approach to adjuvant therapy in patients with resected adenocarcinoma of the pancreas. We focus on adjuvant chemotherapy and chemoradiation, and their impact on overall survival in this subgroup of patients.
|Original language||English (US)|
|Journal||European journal of Clinical and Medical Oncology|
|State||Published - Sep 9 2010|
ASJC Scopus subject areas